Market Place
Sourcing Support
Hep B biotech Antios closed after FDA hold proved insurmountable
22 Sep 2023 //
FIERCE BIOTECH
Antios hep B drug slows viral rebound, but FDA hold casts shadow
27 Jun 2022 //
FIERCEBIOTECH
Antios` ATI-2173 Demonstrates Suppression of Hepatitis B Virus in PIIa Study
25 Jun 2022 //
PRNEWSWIRE
Antios Announces Oral Presentations on three Hepatitis B Virus Programs
08 Jun 2022 //
PRNEWSWIRE
FDA Puts Clinical Hold on Antios` HBV Therapy, Ends Collaboration with Assembly
01 Jun 2022 //
TRIALSITENEWS
Heart trouble report & clinical hold spell end of Antios, Assembly Bio alliance
26 May 2022 //
MEDCITYNEWS
Antios Tx Announces Notice of Allowance for U.S. Patent on Phosphoramidates
26 Apr 2022 //
PRNEWSWIRE
Antios` ATI-2173 Suppresses Hepatitis B Virus in Phase 1b and 2a Studies
30 Mar 2022 //
PRNEWSWIRE
Antios Therapeutics &Arbutus Biopharma Announce First Patient Dosed in Phase 2a
14 Dec 2021 //
GLOBENEWSWIRE
Antios Partners with IRBM, INGM and OSR to Acquire 4th Gen HBV CAMs
15 Nov 2021 //
BIOSPACE
Antios Raises $75M in a Series B-1 Funding for HBV
03 Nov 2021 //
PRNEWSWIRE
Antios Therapeutics` hep B candidate gets another round of applause
03 Nov 2021 //
ENDPTS
Antios Therapeutics, Assembly Biosciences Enter Clinical Collaboration
19 Oct 2021 //
CONTRACTPHARMA
Antios and Assembly Announce Clinical Collab Agreement of ATI-2173& Vebicorvir
19 Oct 2021 //
GLOBENEWSWIRE
Antios to Participate in H.C. W. 2nd Annual Hepatitis B Virus Conference
07 Oct 2021 //
PRNEWSWIRE
Antios Therapeutics Announces Presentation at ICE-HBV Toronto Annual Symposium
22 Sep 2021 //
PRNEWSWIRE
Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs
10 Aug 2021 //
GLOBENEWSWIRE
Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs
10 Aug 2021 //
GLOBENEWSWIRE
Arbutus and Antios Announce Clinical Collaboration Agreement to Evaluate AB-729
29 Jun 2021 //
GLOBENEWSWIRE
Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity
23 Jun 2021 //
GLOBENEWSWIRE
Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173
21 Apr 2021 //
GLOBENEWSWIRE
The hunt for a hep B cure heats up, as Antios Therapeutics preps for an IPO
13 Apr 2021 //
GLOBNEWSWIRE
Antios Therapeutics Raises $96 Million in a Series B Financing
13 Apr 2021 //
GLOBNEWSWIRE
Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173
25 Jan 2021 //
BIOSPACE
Antios Therapeutics Presents at EASL Digital International Liver Congress 2020
03 Sep 2020 //
PRNEWSWIRE
Antios Therapeutics Announces Publication Describing Profile of ATI-2173
01 Sep 2020 //
PRNEWSWIRE
Antios Therapeutics Announces Publication of Preclinical Profile of ATI-2173
31 Aug 2020 //
PRNEWSWIRE
Antios Therapeutics Announces Notice of Allowance for a U.S. Patent ATI-2173
24 Feb 2020 //
PR NEWSWIRE
Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173
12 Feb 2020 //
PR NEWSWIRE
